Menopause Treatment Market Expected to Witness CAGR of 6.10%, Fueled by Economic Growth
Global Menopause Treatment Market is expected to have a market value of USD 17.3 Billion by 2032 at 6.10% CAGR during the forecast period.
The Menopause Treatment
market is experiencing a significant shift, with a growing emphasis on natural
alternatives such as Herbal Menopause Treatments and traditional approaches
like Hormone Replacement Therapy (HRT). Menopause, a natural biological process
marking the end of a woman's reproductive years, often comes with uncomfortable
symptoms like hot flashes, mood swings, and sleep disturbances. As awareness of
the potential risks associated with conventional HRT increases, there is a
rising interest in herbal remedies.
Herbal Menopause Treatments have gained traction due to their perceived safety and
minimal side effects. Women are exploring options like black cohosh, red
clover, and soy-based supplements to alleviate symptoms. These herbal
alternatives are believed to provide relief without the potential risks linked
to synthetic hormones. The market is witnessing a surge in demand for botanical
solutions, driven by a preference for more holistic and nature-based approaches
to menopause management.
On the other hand, Hormone
Replacement Therapy remains a prominent choice for many women seeking effective
relief from menopausal symptoms. HRT involves replacing hormones, such as
estrogen and progesterone, to balance the decline in natural hormone production
during menopause. While HRT has proven efficacy in symptom management, concerns
about potential risks, including an increased risk of certain cancers and
cardiovascular issues, have led to a more cautious approach.
Major Key
Players:
MRFR recognizes the Menopause Treatment Companies are — Novo Nordisk A/S (Denmark),
Pfizer Inc. (US), Allergan (Ireland), Eli Lily and Company (US), Emcure
Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc.
(India), Teva Pharmaceuticals (Israel), Merck & Co., Inc.
(US), Abbott Laboratories (US).
Segment Analysis
The global menopause
treatment market is segmented based on treatment and distribution channel.
The global menopause
treatment market based on the treatment has been segmented into hormonal
treatment and non-hormonal treatment. The hormonal treatment segment is further
segmented into estrogen, progesterone, and combination. The non-hormonal
treatment is further segmented into anti-depressants and others.
Based on distribution
channel, the menopause treatment market is segmented into hospital pharmacies,
retail pharmacies, and online stores.
Regional
Analysis
The global menopause market,
based on region, has been divided into the Americas, Europe, Asia-Pacific, and
Middle East & Africa.
The Americas has been
segmented into North America and Latin America, with the North America market
further divided into the US and Canada. The Americas led the market and
accounted for the largest share in 2019 owing to the increasing product
approvals and high uptake of new technology. For instance, in July 2017,
AMAG Pharmaceuticals, Inc. (US) launched Intrarosa (prasterone) for the
treatment of moderate to severe dyspareunia a symptom of vulvar and vaginal
atrophy (VVA), due to menopause. Thus, such strategies employed by major
players aid in the increased growth rate for the Americas menopause treatment
industry.
The European menopause
treatment market has been further segmented into Western Europe and Eastern
Europe. The Western Europe menopause treatment market has further been
classified into Germany, France, the UK, Italy, Spain, and the rest of Western
Europe. Europe follows the Americas in the global menopause treatment market.
The increasing inclination of companies towards female technology (femtech) is
boosting the growth of the menopause treatment market in European countries.
Many digital health start-ups have identified this opportunity and are offering
B2C digital health tools, such as mobile apps, to guide menopausal women
through this phase with lifestyle intervention tips and online telehealth
consultations. As a result, the region is expected to show significant growth
in the menopause treatment market.
The menopause treatment
market in Asia-Pacific has been segmented into China, India, Japan, South
Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to
register the highest growth rate over the forecast period from 2020 to 2032.
This is owing to the growing penetration of the women’s health sector,
increasing awareness about the betterment of the women’s health, and the
growing number of educational campaigns related to the benefits of hormone
replacement therapy in China, Japan, India, and Australia.
The Middle East &
Africa menopause treatment market is segmented Saudi Arabia, the
United Arab Emirates (UAE), Oman, Kuwait, Qatar, and the rest of the Middle
East & Africa. The negative connotation of menopause has resulted in a
negative attitude towards menopause in premenopausal women. However, with the
increasing awareness created by private companies, the scenario is expected to
change in the next ten years.
Browse Related Reports:
Intracranial-Pressure
Monitoring
For More
Information, Please Visit @ Market
Research Future
Comments
Post a Comment